Continuing development of vaccines and monoclonal antibodies against Zika virus

Woodson, Sara E.; Morabito, Kaitlyn M.

doi:10.1038/s41541-024-00889-x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Preprint1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?

Cagigi,

Tinnirello,

Iannolo

et al. 2024

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?

Cagigi,

Tinnirello,

Iannolo

et al. 2024

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Global burden and incidence trends of zika virus infection among women aged 15–49 years from 2011 to 2021: A systematic analysis

Qin,

Wang,

Liu

et al. 2024

Journal of Infection and Public Health

View full text Add to dashboard Cite

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Nkolola,

Hope,

Guan

et al. 2024

Preprint

View full text Add to dashboard Cite

Zika virus (ZIKV) is a mosquito-borne flavivirus that caused a global pandemic in 2016-2017 with continued ongoing transmission at low levels in several countries. In the absence of an approved ZIKV vaccine, neutralizing monoclonal antibodies (mAbs) provide an option for the prevention and treatment of ZIKV infection. Previous studies identified a potent neutralizing human mAb ZIKV-117 that reduced fetal infection and death in mice following ZIKV challenge. In this study, we report exquisite potency of ZIKV-117 in a titration study in rhesus macaques to protect against ZIKV challenge. We show complete protection at a dose of 0.016 mg/kg ZIKV-117, which resulted in median serum concentrations of 0.13 ug/mL. The high potency of this mAb supports its potential clinical development as a novel biotherapeutic intervention for ZIKV.

show abstract

Continuing development of vaccines and monoclonal antibodies against Zika virus

Cited by 4 publications

References 62 publications

Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?

Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?

Global burden and incidence trends of zika virus infection among women aged 15–49 years from 2011 to 2021: A systematic analysis

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Contact Info

Product

Resources

About